Radar Therapeutics
Radar builds programmable mRNA medicines that read cellular RNA signatures to deliver targeted therapy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $13.4M
AI Company Overview
Radar builds programmable mRNA medicines that read cellular RNA signatures to deliver targeted therapy.
OncologyRare Disease
Technology Platform
RADAR combines single‑cell transcriptomic mining, RNA‑editing sensor design, and programmable logic gates to create mRNA therapeutics that activate only in cells expressing predefined RNA signatures.
Opportunities
Radar’s programmable mRNA platform can unlock new therapeutic indications and attract partnerships with pharma seeking safer RNA medicines.
Risk Factors
Technical challenges in sensor specificity, scale‑up manufacturing, and regulatory acceptance could delay development and commercialization.
Competitive Landscape
Key competitors include Moderna, BioNTech, and Arcturus, which focus on conventional mRNA delivery; Radar differentiates by adding cell‑type‑specific sensing to improve safety and efficacy.